Truist Securities Maintains Buy on Allogene Therapeutics, Lowers Price Target to $10

Benzinga · 05/14/2025 16:07
Truist Securities analyst Asthika Goonewardene maintains Allogene Therapeutics (NASDAQ:ALLO) with a Buy and lowers the price target from $14 to $10.